Savaş GÜZEL, Özlem YILDIZ, Aysun ÜNAL, Ali Rıza KIZILER, Tevfik GÜLYAŞAR, Eda ÇELİK GÜZEL, Çiğdem FİDAN

Alzheimer hastalığında doublecortin-like kinaz-1 düzeyleri ve oksidan durumu

Amaç: Alzheimer hastalığı (AH); merkezi sinir sisteminin çeşitli kısımlarında nöronları etkileyen progresif bir nörodejeneratif hastalıktır. Yeni keşfedilen bir protein olan Doublecortin like kinaz-1 (DCLK-1) mikrotübül ilişkili proteinlerden biridir. Amacımız AH’de DCLK-1’in rolünü ve oksidatif stresle ilişkisini araştırmaktır.Gereç ve Yöntem: Çalışma grubu bellek bozuklukları nedeniyle polikliniğe başvuran AH tanısı konan 60 hasta ve 30 sağlıklı bireyden oluşturuldu. Hasta ve kontrol grubunun serumlarında DCLK-1, tau protein ve çinko düzeyleri ölçüldü. Oksidatif stresin varlığını değerlendirmek için malondialdehit (MDA), protein karbonil grup (PCG), protein tiyol grup (PTG), glutatyon (GSH) ve katalaz düzeyleri saptandı. Demans derecesi Mini Mental Durum Muayenesi (MMSE) ve Demansın Klinik Evrelendirilme Ölçeği (CDR) ile evrelendirildi. Bulgular: Serum DCLK-1 ve tau düzeyleri AH’da kontrol grubuna göre anlamlı olarak yüksek saptandı. AH olan grupta MDA, PCG düzeyleri anlamlı olarak yüksek ve GSH, katalaz düzeyleri anlamlı olarak düşük saptandı. DCLK-1 ve MDA düzeyleri ciddi AH olan grupta hafif gruba göre anlamlı olarak yüksek saptandı. AH grubunda DCLK-1 ile CDR ve MDA arasında pozitif korelasyon ve çinko, MMSE ve B12 vitamini değerleri arasında negatif korelasyon saptandı Sonuç: AH’da DCLK-1 düzeylerinin artışı ve risk faktörleri ile ilişkili bulunması hastalığın değerlendirilmesinde yeni bir belirteç olabileceğini göstermektedir.

Anahtar Kelimeler:

DCLK-1, tau, Alzheimer Hastalığı, çinko, oksidatif stres

Doublecortin-like kinase 1 levels and oxidant status in Alzheimer's disease

Purpose: Alzheimer disease (AD) is a progressive neurodegenerative disease that affects the neurons in various parts of the central nervous system. Recently discovered protein Doublecort like kinase-1 (DCLK-1) is one of the microtubule-associated protein. Our goal is to investigate the relationship of the role of the DCLK-1 in AD disease and oxidative stress.Material and Methods: The study included Alzheimer-disease-diagnosed 60 patients admitted to the clinic with memory disorders, and 30 healthy subjects. In the serum of patient and control group, DCLK-1, tau protein and zinc levels were measured. To assess the presence of oxidative stress, malondialdehyde (MDA), protein carbonyl group (PCG), protein thiol groups (PTG), glutathione (GSH) and catalase levels were detected. Dementia level was staged with Mini-Mental State Examination (MMSE) and Dementia Clinical Staging Scale (CDR). Results: Serum DCLK-1 and tau levels were determined significantly higher in AD compared to the control group). In the group with AD, levels of MDA, and PCG levels were significantly higher and GSH, catalase levels were determined significantly lower. DCLK-1 and MDA levels were determined significantly higher in the group with severe AD compared to the group with mild AD. In AD group, a positive correlation between DCLK-1 and, CDR and MDA; and negative correlation was found between MMSE and B12 vitamin Conclusions: The presence of a relation with increase in DCLK1 levels in AD and risk factors shows that it can be a new marker in assessing the disease.

Keywords:

DCLK-1, tau, Alzheimer's disease, zinc, oxidative stress,

PDF

___

1. Gilman S. Alzheimers disease. Perspect Biol Med. 1997;40:230-45.
2. Lleó A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med. 2006;57:513-33.
3. Markesbery WR, Ehmann WD (Çev. B Bilgiç). Alzheimer Hastalığında oksidatif gerilim. In Alzheimer Hastalığı (Eds RD Terry, R Katzman, KL Bick, SS Sisodia (Çev. Ed. H Gürvit):401-14. İstanbul, Yelkovan Yayınclık, 2001.
4. Smith MA, Nunomura A, Lee HG, Zhu X, Moreira PI, Avila J et al. Chronological primacy of oxidative stress in Alzheimer disease. Neurobiol Aging. 2005;26:579-80.
5. Repetto MG, Reides CG, Evelson P, Kohan S, de Lustig ES, Llesuy SF. Peripheral markers of oxidative stress in probable Alzheimer patients. Eur J Clin Invest. 1999;29:643-9.
6. Akkuş İ. Serbest Radikaller ve Fizyopatolojik Etkileri. Ankara, Mimoza Yayınları, 1995.
7. Nizamlıoğlu M, Tiftik MA. Glutatyon peroksidaz (GSH-Px) enziminin vitamin E ve selenyum ile ilişkisi. Türk Vet Hek Derg. 1992;1:10-3.
8. Mason RP, Walter MF, Mason PE. Effect of oxidative stress on membran structure small angle Xray diffraction analyeses. Free Radic Biol Med. 1997:3:419-25.
9. Delibaş N, Özcankaya R, Özgüner MF, Boz F. Bilişsel durum değişiklikleri, depresif ve psikotik belirtilerle serbest radikal aktivitesinin ilişkisi. Turk Psikiyatri Derg. 1996;1:46-52.
10. Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia. Schizophr Res. 1996;1:1-17.
11. Takeda A, Tamano H. Insight into zinc signaling from dietary zinc deficiency. Brain Res Rev. 2009;62:33-44.
12. Bhatnagar S, Taneja S. Zinc and cognitive development. Br J Nutr. 2001;85:139-45.
13. Mohandas E, Rajmohan V, Raghunath B. Neurobiology of Alzheimer's disease. Indian J Psychiatry. 2009;51:55-61.
14. Octave JN, Pierrot N. Alzheimer's disease: cellular and molecular aspects. Bull Acad Natl Med. 2008;192:323-31.
15. Markesbery WR, Carney JM. Oxidative alterations in Alzheimer’s disease. Brain Pathol. 1999;9:133-46.
16. Burgess HA, Reiner O. Doublecortin-like kinase is associated with microtubules in neuronal growth cones. Mol Cell Neurosci. 2000;16:529–41.
17. Nawabi H, Belin S, Cartoni R, Williams PR, Wang C, Latremolière A et al. Doublecortin-like kinases promote neuronal survival and induce growth cone reformation via distinct mechanisms. Neuron. 2015;88:704-19.
18. Burgess HA, Reiner O. Cleavage of doublecortin-like kinase by calpain releases an active kinase fragment from a microtubule anchorage domain. J Biol Chem. 2001;276:36397-403.
19. Koizumi H, Fujioka H, Togashi K, Thompson J, Yates JR, Gleeson JG et al. DCLK1 phosphorylates the microtubule-associated protein MAP7D1 to promote axon elongation in cortical neurons. Dev Neurobiol. 2016;9. doi: 10.1002/dneu.22428.
20. Le Hellard S, Havik B, Espeseth T, Breilid H, Lovlie R, Luciano M et al. Variants in doublecortin- and calmodulin kinase like 1, a gene up-regulated by BDNF, are associated with memory and general cognitive abilities. PLoS One. 2009;4:e7534.
21. Havik B, Degenhardt FA, Johansson S, Fernandes CP, Hinney A, Scherag A et al. DCLK1 variants are associated across schizophrenia and attention deficit/hyperactivity disorder. PLoS One. 2012;7:e35424.
22. Jeong YH, Kim JM, Yoo J, Lee SH, Kim HS, Suh YH. Environmental enrichment compensates for the effects of stress on disease progression in Tg2576 mice, an Alzheimer's disease model. J Neurochem. 2011;119:1282-93.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition Text Revision (DSM IV TR). Washington, DC, American Psychiatric Association, 2000.
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDSARDRA work group under the auspices of department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34:939-44.
25. Beutler E, Duron E, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med. 1963;61:882-8.
26. Goth L. A simple method for determination of serum catalase activity and revision of reference range. Clin Chim Acta. 1991;196:143–51.
27. Reznick Z, Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol. 1994;233:357-63.
28. Beuge JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978;52:302-10.
29. Gardiner J, Overall R, Marc J. The microtubule cytoskeleton acts as a key downstream effector of neurotransmitter signaling. Synapse. 2011;65:249-56.
30. Xia Q1, Liao L, Cheng D, Duong DM, Gearing M, Lah JJ et al. Proteomic identification of novel proteins associated with Lewy bodies. Front Biosci. 2008;13:3850-6.
31. Pedotti P, t Hoen PA, Vreugdenhil E, Schenk GJ, Vossen RH, Ariyurek Y et al. Can subtle changes in gene expression be consistently detected with different microarray platforms? BMC Genomics. 2008;9:124.
32. Brewer GJ, Kanzer SH, Zimmerman EA, Molho ES, Celmins DF, Heckman SM et al. Subclinical zinc deficiency in Alzheimer’s disease and Parkinson’s disease. Am J Alzheimers Dis Other Demen. 2010;25:572-75.
33. Dong J, Robertson JD, Markesbery WR, Lovell MA. Serum zinc in the progression of Alzheimer’s disease. J Alzheimers Dis. 2008;15:443-50.
34. Praticò D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Trojanowski. Increase of brain oxidative stress in mild cognitive impairment. A possible predictor of Alzheimer disease. Arch Neurol. 2002;59:972–6.
35. Baldeiras I, Santana I, Proença MT, Garrucho MH, Pascoal R, Rodrigues A, et al. Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. J Alzheimers Dis. 2008;15:117- 28.
36. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology. 2005;64; 1152–6.
37. Fernandes MA, Santana I, Januario C, Cunha L, Oliveira CR. Decreased superoxide dismutase in erythrocytes from patients with Alzheimer's disease. Med Sci Res. 1993;21:679-682.